Sana Biotechnology Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Sana Biotechnology Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Seattle
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SANA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001770121
- EIN
- 83-1381173
Board of directors
-
Alise Reicin · DirectorSince 2023
-
Douglas G. Cole · DirectorSince 2023
-
Hans Edgar Bishop · DirectorSince 2023
-
Joshua H. Bilenker · DirectorSince 2023
- Since 2023
-
Michelle Seitz · DirectorSince 2023
-
Patrick Y. Yang · DirectorSince 2023
-
Richard Mulligan · DirectorSince 2023
-
Robert L. Rosiello · DirectorSince 2025
- Since 2023
-
Steve Harr · Director · President & CEOSince 2023
Chief executives
Steve Harr
· President & CEO
Dates unknown
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
67.3%
-
85.8%
-
91.9%
Board connections
8 of this board's directors also sit on 21 other boards.
- via Hans Edgar Bishop and Robert Nelsen
- via Hans Edgar Bishop
- via Richard Mulligan
- via Mary Agnes Wilderotter
- via Douglas G. Cole
- via Mary Agnes Wilderotter
- via Douglas G. Cole
- via Mary Agnes Wilderotter
- via Michelle Seitz
- via Alise Reicin
- via Richard Mulligan
- via Robert Nelsen
- via Mary Agnes Wilderotter
- via Michelle Seitz
- via Michelle Seitz
- via Mary Agnes Wilderotter
- via Robert Nelsen
- via Alise Reicin
- via Robert L. Rosiello
- via Alise Reicin
- via Robert Nelsen
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 27, 2026 | PATEL DHAVALKUMAR DHIRAJLAL Officer (EVP, Chief Scientific Officer) | Shares withheld for tax | −41,158 | $4.11 | $169,159 |
| Aug 26, 2026 | PATEL DHAVALKUMAR DHIRAJLAL Officer (EVP, Chief Scientific Officer) | Option exercise | +125,000 | — | — |
| Jul 6, 2026 | Hans Edgar Bishop Director | Grant or award | +6,297 | — | — |
| Apr 6, 2026 | Hans Edgar Bishop Director | Grant or award | +7,763 | — | — |
| Mar 9, 2026 | Steve Harr Director, Officer (President & CEO) | Shares withheld for tax | −11,526 | $3.13 | $36,076 |
| Mar 9, 2026 | Wyrick Susan D. Officer (See Remarks) | Shares withheld for tax | −3,342 | $3.13 | $10,460 |
| Mar 9, 2026 | Steve Harr Director, Officer (President & CEO) | Shares withheld for tax | −12,819 | $3.10 | $39,739 |
| Mar 9, 2026 | Wyrick Susan D. Officer (See Remarks) | Shares withheld for tax | −1,045 | $3.10 | $3,240 |
| Mar 7, 2026 | Steve Harr Director, Officer (President & CEO) | Option exercise | +50,000 | — | — |
| Mar 7, 2026 | Wyrick Susan D. Officer (See Remarks) | Option exercise | +3,250 | — | — |
| Mar 6, 2026 | Steve Harr Director, Officer (President & CEO) | Option exercise | +41,666 | — | — |
| Mar 6, 2026 | Wyrick Susan D. Officer (See Remarks) | Option exercise | +10,416 | — | — |
| Mar 3, 2026 | Wyrick Susan D. Officer (See Remarks) | Shares withheld for tax | −491 | $3.91 | $1,920 |
| Mar 2, 2026 | Wyrick Susan D. Officer (See Remarks) | Option exercise | +1,525 | — | — |
| Jan 5, 2026 | Hans Edgar Bishop Director | Grant or award | +6,157 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.